TO THE EDITOR-We read with interest the experience by Miller et al regarding the tolerance to benznidazole treatment in a cohort of patients affected by chronic Chagas disease in Los Angeles, California [1] . In the last decade, physicians from Europe and the United States have been increasingly observing chronic Chagas disease in Latin American immigrants and have concomitantly been facing uncertainties about how to make a correct diagnosis and treat affected patients [2] . Both these issues have been dealt with in the Latin American literature due to the lack of previous direct experience by physicians from nonendemic areas [3] . In this context, 2 problems recently emerged regarding the treatment of the chronic indeterminate form and the mild cardiomyopathy of Chagas disease: (1) the shift from an attitude limited to counseling and follow-up to a position of actively offering treatment to all adult patients aged 19-50 years based on results indicating a reduced risk of progression of the disease and on new concepts of immunopathogenesis [3] [4] [5] ; (2) the emergence of benznidazole as the best drug option available over nifurtimox (the other drug considered to be active against Trypanosoma cruzi) and posaconazole (an antifungal drug active in murine models) [6] . However, the use of a drug for which there is no direct (firsthand) experience requires the preliminary acquisition of complete information about its side effects and their relative rate of appearance. In this regard, in one of the major textbooks of internal medicine, it is reported that for benznidazole "adverse effects include rash, peripheral neuropathy, and rarely, agranulocytosis" [7] . A meta-analysis including studies published in the literature until October 2008 indicated that between 1% and 18% (median, 10%) of patients discontinued benznidazole treatment due to toxicity [4] . In the US guidelines, it is indicated that approximately "30% of patients experience both dermatologic adverse effects (usually mild to moderate) and a dose-dependent peripheral neuropathy. Bone marrow suppression is rare . . . additional reported adverse effects include anorexia and weight loss, nausea and/or vomiting, insomnia and dysgeusia" [8] .
Moreover, other than the article by Miller et al, few reports have recently addressed the problem of the tolerance of benznidazole both in adults and children [9] [10] [11] [12] [13] [14] [15] ; from the analysis of other studies (mainly conducted to evaluate drug efficacy) [3, [16] [17] [18] [19] , a higher than expected prevalence of dermatologic side effects, as well as higher rates of permanent drug discontinuation, emerge (Table 1) . However, Miller et al underline in their work the high frequency of neuropathy (an expected adverse event) and angioedema (an unexpected adverse event). In this regard, we report our recent experience in Milan, Italy.
Starting from July 2013 we began, with the collaboration of Médecins Sans Frontières, a screening program for Chagas disease directed to Latin American immigrants living in the nothern Italian city of Milan. Diagnosis of Chagas disease was performed through 2 positive serological tests according to World Health Organization recommendations: a chemiluminescent immunoassay with recombinant antigens (Abbott Architect Chagas, Abbott PRISM, Abbott Diagnostics) and an enzyme-linked immunosorbent assay with crude antigen (BioELISA Chagas III, BiosChile). Up to July 2014, 497 subjects (98% born in Central or South America) were enrolled in the study. Forty-four (8.8%) were found to be seropositive for T. cruzi: 39 (88.6%) from Bolivia, 4 (9.3%) from El Salvador, and 1 (2.3%) from Argentina. At present, 23 have completed assessments for cardiac involvement (eg, 12-lead electrocardiogram, chest radiograph, and echocardiogram) and gastrointestinal involvement (eg, esophagogram following the Rezende classification and barium enema). Eighteen patients have started treatment with benznidazole (Abarax, ELEA, Industria Argentina, 100 mg) at a dosage of 5 mg/kg/day in 2 divided doses (maximum dose 300 mg/day) for 60 days. As reported in Table 1 , rash was observed in 6 (55%) patients and was the principal reason of drug discontinuation in 5 of them. Two patients (11%) presented with severe symmetrical polyarthritis that required hospitalization and was the reason of discontinuation of the drug in 1 case. Although arthralgias are well-recognized adverse reactions to benznidazole, at the time of presentation of our first patient with arthritis, to the best of our knowledge, only the article by Carrilero et al [12] had described this adverse event in 3 patients (0.8%). More recently, Aldasoro et al had described arthritis in 6 of 179 patients (3.3%) treated with benznidazole [16] . In their experience, arthritis appeared after a median of 35 days of treatment (range, 25-42 days), an interval that is similar to ours (mean, 27 days), indicating that it is a delayed side effect of the drug. Finally, we would like to comment on the suggestions made by Brazilian authors regarding the use of glucocorticoids to mitigate benznidazole-induced allergic dermatitis and the reinstitution of benznidazole after severe dermatitis [20] .Among our treated patients, we observed a high rate (7/18 [38.8%]) of occult (ie, asymptomatic) strongyloidiasis requiring ivermectin treatment. If patients are not screened and treated for this infestation, steroid use might precipitate a severe hyperinfection syndrome [21] .
Notes

